Arcturus Therapeutics Ltd. (ARCT) Reaches $5.13 After 8.00% Down Move; Hcp (HCP) Sellers Decreased By 9.66% Their Shorts

February 13, 2018 - By Maria Brooks

The stock of Arcturus Therapeutics Ltd. (NASDAQ:ARCT) is a huge mover today! The stock decreased 9.20% or $0.52 during the last trading session, reaching $5.13. About 92,091 shares traded or 11.98% up from the average. Arcturus Therapeutics Ltd. (NASDAQ:ARCT) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 9 months negative chart setup for the $ company. It was reported on Feb, 13 by Barchart.com. We have $4.72 PT which if reached, will make NASDAQ:ARCT worth $ less.

Hcp Incorporated (NYSE:HCP) had a decrease of 9.66% in short interest. HCP’s SI was 8.82 million shares in February as released by FINRA. Its down 9.66% from 9.76 million shares previously. With 3.15M avg volume, 3 days are for Hcp Incorporated (NYSE:HCP)’s short sellers to cover HCP’s short positions. The SI to Hcp Incorporated’s float is 1.89%. The stock decreased 2.10% or $0.48 during the last trading session, reaching $22.37. About 3.30M shares traded. HCP, Inc. (NYSE:HCP) has risen 8.01% since February 13, 2017 and is uptrending. It has underperformed by 8.69% the S&P500.




Arcturus Therapeutics Ltd. operates as an RNA medicines company. The company has market cap of $. The Company’s RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics. It currently has negative earnings. The firm owns LUNAR lipid-mediated delivery and Unlocked Nucleomonomer Agent technology, including UNA Oligomers, which are covered by its patent portfolio, including 120 patents and patent applications issued in the United States, Europe, Japan, China, and other countries.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.38, from 1.23 in 2017Q2. It worsened, as 54 investors sold HCP, Inc. shares while 188 reduced holdings. 43 funds opened positions while 163 raised stakes. 411.39 million shares or 0.00% less from 411.39 million shares in 2017Q2 were reported. Alliancebernstein Lp holds 1.16M shares or 0.02% of its portfolio. Segall Bryant & Hamill Ltd Company reported 11,560 shares. Van Hulzen Asset Management Ltd Liability reported 7,744 shares. 47,137 are owned by Panagora Asset Mgmt Inc. Moreover, Cornerstone Inc has 0% invested in HCP, Inc. (NYSE:HCP). Asset Mngmt invested 0.04% in HCP, Inc. (NYSE:HCP). Stratos Wealth Prtn Ltd owns 8,158 shares. Charter Tru, New Hampshire-based fund reported 8,025 shares. North Star Investment Corp invested in 0.01% or 1,629 shares. The Connecticut-based Eagle Ridge Inv Mngmt has invested 0.04% in HCP, Inc. (NYSE:HCP). Oakbrook Invs Lc invested in 20,291 shares or 0.04% of the stock. Edge Wealth Mngmt Limited Liability Com, New York-based fund reported 200 shares. Weiss Multi invested 1.13% of its portfolio in HCP, Inc. (NYSE:HCP). Amica Pension Fund Board Of Trustees owns 17,535 shares for 0.06% of their portfolio. First Interstate Bancorp reported 965 shares.

HCP, Inc. is an independent hybrid real estate investment trust. The company has market cap of $10.58 billion. The fund invests in real estate markets of the United States. It has a 19.78 P/E ratio. It primarily invests in properties serving the healthcare industry including sectors of healthcare such as senior housing, life science, medical office, hospital and skilled nursing.

Among 20 analysts covering HCP (NYSE:HCP), 5 have Buy rating, 1 Sell and 14 Hold. Therefore 25% are positive. HCP had 70 analyst reports since September 8, 2015 according to SRatingsIntel. The rating was upgraded by Goldman Sachs to “Neutral” on Friday, July 8. The stock of HCP, Inc. (NYSE:HCP) has “Buy” rating given on Thursday, November 2 by Mizuho. The company was upgraded on Friday, December 15 by J.P. Morgan. As per Tuesday, August 23, the company rating was maintained by UBS. The firm has “Equal-Weight” rating given on Thursday, December 14 by Morgan Stanley. The firm earned “In-Line” rating on Monday, March 27 by Evercore. Stifel Nicolaus maintained the stock with “Hold” rating in Thursday, November 2 report. The stock of HCP, Inc. (NYSE:HCP) has “Hold” rating given on Tuesday, August 1 by BMO Capital Markets. Bank of America downgraded HCP, Inc. (NYSE:HCP) rating on Friday, September 22. Bank of America has “Hold” rating and $31.0 target. The firm has “Equal-Weight” rating given on Monday, September 25 by Morgan Stanley.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.